Celularity Revolutionizing Cancer Treatment: The Breakthrough of Stem Cell Therapy
![celularity-logo](https://nationalstemcelltherapy.com/wp-content/uploads/2023/07/celularity-logo-1024x724.jpg)
A New Era in Oncology In an exciting development for the field of oncology, Celularity Inc., a leading biotechnology company, is set to present compelling in vivo data at the AACR Annual Meeting 2024. This data showcases the significant impact of their groundbreaking stem cell therapy, PT-CD16, in reducing cancer tumors. Derived from human placental […]
Updated Invectys and CTMC announce FDA clearance of IND application for anti-HLA-G CAR-T cell therapy
![Invectys logo](https://nationalstemcelltherapy.com/wp-content/uploads/2022/12/Invectys-logo.jpg)
HOUSTON, Texas, Dec. 20, 2022 (GLOBE NEWSWIRE) — Invectys, Inc. and CTMC, a joint venture between MD Anderson Cancer Center and National Resilience, Inc., today announced Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for a Phase 1/2a clinical study of IVS-3001, Invectys’s lead engineered human leukocyte antigen A (HLA-G) targeting chimeric antigen […]
IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma
![IN8bio logo](https://nationalstemcelltherapy.com/wp-content/uploads/2022/12/in8biologo-1024x507.jpg)
NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial of a genetically modified […]